Accelerate the Development of T-Cell Engagers in Autoimmune Diseases by Expanding Targets Beyond B-Cells, Reducing CRS Toxicities, & Achieve Deep Depletion & Clinical Success
The 2nd T-Cell Engager for Autoimmune Disease Summit arrives at a pivotal moment for the field as autoimmune TCEs rapidly transition from oncology-inspired concepts into one of the industry’s most exciting and heavily invested therapeutic modalities. Following major investments and partnerships from companies including Gilead, UCB, Sanofi, and Boehringer Ingelheim, the focus has shifted from proving the modality works to optimizing safety, durability, and clinical differentiation.
As the industry’s only dedicated meeting focused exclusively on autoimmune T-cell engagers, this summit brings together 80+ leaders across discovery, translational, preclinical, clinical, and business development to tackle the field’s most urgent challenges. Discussions will explore how to reduce CRS toxicities, improve tissue-selective immune depletion, engineer next-generation engager architectures, expand beyond B-cell targets, and translate early clinical insights into safer, more effective therapies.
With 15+ new speakers, emerging clinical datasets, 2 deep-dive workshops, and 8+ hours of networking including speed networking and interactive roundtables, this is the must-attend forum to benchmark strategies, build partnerships, and shape the future of autoimmune T-cell engager development.
Great collection of experts who were willing to share their data and experiences in the TCE AID field. Was helpful to pressure test my own thinking in this area against others. I enjoyed the presentations as well as the opportunity to network. The 2 days I attended had just the right number of presentations and breaks to maintain my interest and focus.
Executive Director, GlaxoSmithKline
Content was well-thought, and speakers were the right ones, bringing senior expertise, practical and real data and knowledge, open discussions. I have been at several small conferences in Boston this year, this one and the last TCE in oncology one was exceptionally well run. Anjuli has the perfect balance between technical/scientific know-how and savoir faire with coordinating people timelines and tasks - I look forward to the next one.
Chief Medical Officer, ModeX Therapeutics
Hearing about so many different approaches to TCEs. Speaking with people interested in the field and getting their feedback.
Vice President - Clinical Development, Culllinan Therapeutics
Explore the Full Event Guide
- 15+ New Expert Speakers Sharing Exclusive Insights Across Discovery, Translational, Clinical, and Regulatory Development for Autoimmune T-Cell Engagers
- 8+ Hours of Dedicated Networking Opportunities Including Speed Networking, Interactive Roundtables, Poster Sessions, and Collaborative Discussion Sessions
- 2 Deep-Dive Workshops Focused on TCE Engineering, CRS Mitigation, Translational Modelling, and Clinical Development Strategies
- New Clinical Data-Focused Sessions Within the “Illuminating TCEs in the Clinic for Autoimmune Disease” Theme Highlighting Emerging Safety, Efficacy, and Dosing Learnings
- Expanded Discussions on Precision Target Discovery, Co-Stimulation, Tissue Penetration, and Next-Generation Immune Modulation Strategies Driving the Future of Autoimmune TCEs
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover the latest strategies to engineer safer, more effective autoimmune T-cell engagers through expert-led case studies, clinical data presentations, panel discussions, and interactive workshops.
Partner With Us
Showcase your technologies, platforms, and services to biotech and pharma leaders actively developing next-generation autoimmune T-cell engagers and seeking partners to accelerate discovery, translation, and clinical success.
Join Autoimmune T-Cell Engager Leaders
Connect with discovery, translational, preclinical, and clinical experts driving the next generation of autoimmune T-cell engagers through innovation in target discovery, molecule engineering, and clinical development.